CCL3 and lung cancer: Statins inhibit chemokine (C-C motif) ligand 3 (CCL3) secretion by primary lung cancer cells and suppress IL-6 and CCL2 production by mesenchymal stromal cells (MSCs), and disrupt the communication between lung cancer cells and MSCs (Galland et al., 2020).